{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:24:27Z","timestamp":1751703867574},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,26]]},"DOI":"10.7759\/cureus.35497","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T02:25:26Z","timestamp":1677464726000},"source":"Crossref","is-referenced-by-count":1,"title":["Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Sushan","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avani","family":"Mohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shodunke","family":"Temitope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa JI","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021, 8:777861. 10.3389\/fmed.2021.777861","journal-title":"Front Med (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2021.266","article-title":"Euglycemic diabetic ketoacidosis (EDKA) in a patient receiving dapagliflozin","volume":"17","author":"Sethi SM","year":"2021","unstructured":"Sethi SM, Vohra M, Ali SA. Euglycemic diabetic ketoacidosis (EDKA) in a patient receiving dapagliflozin. Acta Endocrinol (Buchar). 2021, 17:266-9. 10.4183\/aeb.2021.266","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry RR","year":"2012","unstructured":"Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012, 66:446-56. 10.1111\/j.1742-1241.2012.02911.x","journal-title":"Int J Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","unstructured":"9. Pharmacologic approaches to glycemic treatment. standards of medical care in diabetes\u20142022. Diabetes Care. 2022, 45:S125-43. 10.2337\/dc22-S009","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan K","year":"2019","unstructured":"Donnan K, Segar L. SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019, 846:23-9. 10.1016\/j.ejphar.2019.01.002","journal-title":"Eur J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for\u00a0euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry RJ","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, Shulman GI. Dehydration and insulinopenia are necessary and sufficient for\u00a0euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019, 10:548. 10.1038\/s41467-019-08466-w","journal-title":"Nat Commun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020228","article-title":"Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report","volume":"99","author":"Lee IH","year":"2020","unstructured":"Lee IH, Ahn DJ. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report. Medicine (Baltimore). 2020, 99:e20228. 10.1097\/MD.0000000000020228","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata F","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al.. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021, 11:10293. 10.1038\/s41598-021-89752-w","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/139799-life-threatening-acidosis-with-metformin-and-dapagliflozin-combination-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:05Z","timestamp":1707508445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/139799-life-threatening-acidosis-with-metformin-and-dapagliflozin-combination-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,26]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.35497","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,26]]}}}